Senti Bio to Participate in Chardan's 6th Annual Genetic Medicines Conference
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that co-founder and CEO, Tim Lu, CFO, Deb Knobelman, and CMDO, Kanya Rajangam will participate in a Fireside Chat at the Chardan’s 6th Annual Genetic Medicines Conference on Monday, October 3, 2022, at 1:30 PM ET. Tim Lu will also participate in a panel on Gene Regulation on Tuesday, October 4, 2022, at 9:30 AM ET.
A live webcast of the Fireside Chat can be accessed under the Events & Presentations section of the Senti Bio website under the Investors tab and will be available for 120 days following the presentation.
About Senti Bio
Our synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with Gene Circuit technologies, to target particularly challenging liquid and solid tumor oncology indications. Our lead development candidate is SENTI-202 for the treatment of acute myeloid leukemia (AML). Additional CAR-NK programs include SENTI-301 for the treatment of hepatocellular carcinoma (HCC) and SENTI-401 for the treatment of colorectal cancer (CRC). We have also demonstrated the breadth of our Gene Circuits in other modalities and diseases outside of oncology and have executed partnerships with Spark Therapeutics and BlueRock Therapeutics to advance these capabilities.
Availability of Other Information About Senti Biosciences, Inc.
Find more information at sentibio.com
Contact Senti Bio: Deb Knobelman, PhD, CFO [email protected] Media: Kelli Perkins [email protected]
Focus on Customer Experience â€“ Using Artificial Intelligence to Transform the Contact Center
Ensuring Cybersecurity and Privacy with a Hybrid Workforce
The Mission: Ensure a Trusted Communications Ecosystem for Digital Transformation